Todd Shriber

Todd Shriber

InvestorPlace Contributor

Recent Articles

Ideanomics Isn’t the Worst Idea. It’s Not the Best One, Either.

By Todd Shriber, InvestorPlace Contributor

Ideanomics was good for something else last year: It delivered the volatility that fans of penny stocks so desperately crave. In December alone, the stock posted three intraday moves of at least 6%, a 10.61% gain and a 20.58% loss. Its 52-week range was 28 cents to $4.75 and it finished 2020 621% above its 52-week low, but 58.11% below its high.

3 Telemedicine Stocks Due for a Post-Covid Check-Up

By Todd Shriber, InvestorPlace Contributor

Telemedicine stocks provide investors with an avenue to one of the truly disruptive parts of the healthcare sector.

7 Names In Danger of Joining the Shamed Ranks of Delisted Stocks

By Todd Shriber, InvestorPlace Contributor

Some investors just can't help themselves. They love companies with low share prices. However, those equities come with an array of risks, including increased probability that when the $5 and $1 marks are breached, these names can join the ranks of delisted stocks.

Novavax Is Inching Closer, But Its Vaccine Better Be Special

By Todd Shriber, InvestorPlace Contributor

Novavax is trailing the competition in the coronavirus vaccine race, but markets may be punishing NVAX stock too much.

Xpeng Winter Blues Could Be Buying Opportunity Investors Are Looking For

By Todd Shriber, InvestorPlace Contributor

Much of the consternation surrounding Chinese EV makers stems from the Holding Foreign Companies Accountable Act – bipartisan legislation that seeks to hold Chinese companies listed on major U.S. exchanges to the same standards American companies deal with. Not only is this a bipartisan bill, a rarity on Capitol Hill, given his hard line against the world's second-largest economy, President Trump is likely to sign it before leaving office.

Load More